KR102408262B1 - 비시클릭 헤테로사이클 화합물 및 요법에서의 그의 용도 - Google Patents

비시클릭 헤테로사이클 화합물 및 요법에서의 그의 용도 Download PDF

Info

Publication number
KR102408262B1
KR102408262B1 KR1020167019182A KR20167019182A KR102408262B1 KR 102408262 B1 KR102408262 B1 KR 102408262B1 KR 1020167019182 A KR1020167019182 A KR 1020167019182A KR 20167019182 A KR20167019182 A KR 20167019182A KR 102408262 B1 KR102408262 B1 KR 102408262B1
Authority
KR
South Korea
Prior art keywords
methyl
compound
formula
pyridin
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167019182A
Other languages
English (en)
Korean (ko)
Other versions
KR20160095160A (ko
Inventor
지아니 체사리
크리스토퍼 노버트 존슨
스티븐 하워드
제임스 에드워드 하베이 데이
일디코 마리아 벅
카를로테 마리 그리피쓰-존스
고던 색스티
에밀리아노 타마니니
니콜라 엘리자벳 윌셔
Original Assignee
아스텍스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1322755.8A external-priority patent/GB201322755D0/en
Priority claimed from GB201406986A external-priority patent/GB201406986D0/en
Application filed by 아스텍스 테라퓨틱스 리미티드 filed Critical 아스텍스 테라퓨틱스 리미티드
Publication of KR20160095160A publication Critical patent/KR20160095160A/ko
Application granted granted Critical
Publication of KR102408262B1 publication Critical patent/KR102408262B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
KR1020167019182A 2013-12-20 2014-12-19 비시클릭 헤테로사이클 화합물 및 요법에서의 그의 용도 Active KR102408262B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1322755.8 2013-12-20
GBGB1322755.8A GB201322755D0 (en) 2013-12-20 2013-12-20 Bicyclic heterocycle compounds and their uses in therapy
GB201406986A GB201406986D0 (en) 2014-04-17 2014-04-17 Bicyclic heterocycle compounds and their uses in therapy
GB1406986.8 2014-04-17
PCT/GB2014/053778 WO2015092420A1 (en) 2013-12-20 2014-12-19 Bicyclic heterocycle compounds and their uses in therapy

Publications (2)

Publication Number Publication Date
KR20160095160A KR20160095160A (ko) 2016-08-10
KR102408262B1 true KR102408262B1 (ko) 2022-06-10

Family

ID=52134239

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019182A Active KR102408262B1 (ko) 2013-12-20 2014-12-19 비시클릭 헤테로사이클 화합물 및 요법에서의 그의 용도

Country Status (29)

Country Link
US (6) US9783538B2 (enExample)
EP (2) EP3083616B1 (enExample)
JP (3) JP6470756B2 (enExample)
KR (1) KR102408262B1 (enExample)
CN (3) CN115368356B (enExample)
AU (2) AU2014369446C1 (enExample)
BR (2) BR112016014561B1 (enExample)
CA (1) CA2933939C (enExample)
CY (1) CY1124436T1 (enExample)
DK (1) DK3083616T3 (enExample)
ES (1) ES2883289T3 (enExample)
HR (1) HRP20211406T1 (enExample)
HU (1) HUE056297T2 (enExample)
IL (1) IL246239B (enExample)
LT (1) LT3083616T (enExample)
MX (1) MX380469B (enExample)
MY (2) MY186311A (enExample)
NZ (2) NZ719905A (enExample)
PH (1) PH12016501139A1 (enExample)
PL (1) PL3083616T3 (enExample)
PT (1) PT3083616T (enExample)
RS (1) RS62301B1 (enExample)
RU (1) RU2696310C1 (enExample)
SA (1) SA516371360B1 (enExample)
SG (2) SG11201604795RA (enExample)
SI (1) SI3083616T1 (enExample)
SM (1) SMT202100497T1 (enExample)
TW (1) TWI649319B (enExample)
WO (1) WO2015092420A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
PL3083616T3 (pl) 2013-12-20 2021-12-06 Astex Therapeutics Limited Bicykliczne związki heterocykliczne i ich zastosowania w terapii
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3957304A1 (en) 2015-11-25 2022-02-23 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
EA201891904A1 (ru) * 2016-02-24 2019-04-30 Чилдрен'С Хоспитал Оф Истерн Онтарио Рисерч Инститьют Инк. Smc комбинированная терапия для лечения злокачественного новообразования
KR20180135038A (ko) 2016-04-20 2018-12-19 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Ripk2 억제제를 포함하는 컨쥬게이트
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2017278220C1 (en) 2016-06-10 2022-10-13 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
LT3689868T (lt) 2016-12-01 2023-12-27 Arvinas Operations, Inc. Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai
IL272014B2 (en) 2017-07-13 2023-09-01 Io Therapeutics Inc A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
US10363272B2 (en) 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer
WO2020206137A1 (en) 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
JP7656589B2 (ja) 2019-08-26 2025-04-03 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
BR112022005624A2 (pt) 2019-09-25 2022-07-12 Debiopharm Int Sa Regimes de dosagem para tratamento de pacientes com carcinoma de células escamosas localmente avançado
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN120247907A (zh) * 2020-05-04 2025-07-04 大塚制药株式会社 Iap拮抗剂化合物和中间体及其合成方法
PL4146617T3 (pl) * 2020-05-04 2025-12-08 Taiho Pharmaceutical Co., Ltd. Sposoby syntezy bezwodnego kwasu mlekowego
KR20230020942A (ko) * 2020-06-04 2023-02-13 베이진 엘티디 Iap 길항제로서 피리도[2,3-b][1,4]옥사진 또는 테트라하이드로피리도[2,3-b][1,4]옥사제핀
WO2022035610A1 (en) * 2020-08-12 2022-02-17 Archer Daniels Midland Company Purification of 2,5-furandicarboxylic acid, dimethyl ester and other esterified products
AU2021333983A1 (en) 2020-08-27 2023-01-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using MDM2 antagonists
TW202214236A (zh) * 2020-09-14 2022-04-16 美商亞文納營運公司 用於靶向降解雌激素受體之化合物之結晶及非晶形形式
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
MX2024002214A (es) 2021-08-20 2024-03-12 Otsuka Pharma Co Ltd Farmaco de combinacion.
WO2023239422A2 (en) * 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CA3236956A1 (en) * 2021-11-05 2023-05-11 Haihe Biopharma Co., Ltd. Solid dispersion, preparation method therefor, and solid formulation comprising same
JP2025508016A (ja) 2022-03-04 2025-03-21 大鵬薬品工業株式会社 Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法
WO2023230432A1 (en) 2022-05-23 2023-11-30 Inhibrx, Inc. Dr5 agonist and iap antagonist combination therapy
CA3266274A1 (en) 2022-08-31 2024-03-07 Taiho Pharmaceutical Co., Ltd. Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用
CN116375700B (zh) * 2023-01-10 2024-12-17 中国科学院成都生物研究所 一种4-氮杂吲哚啉类化合物及其合成方法与应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
TW202510888A (zh) 2023-07-31 2025-03-16 日商大塚製藥股份有限公司 包含托利那泮(tolinapant)之醫藥組合物及包裝
WO2025235719A1 (en) * 2024-05-08 2025-11-13 Viiv Healthcare Company Dimeric smac mimetics useful in hiv therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143726A1 (en) 2011-04-21 2012-10-26 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
TW218875B (enExample) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
AU2056197A (en) 1996-02-22 1997-09-10 Du Pont Merck Pharmaceutical Company, The M-amidino phenyl analogs as factor xa inhibitors
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
WO1998000401A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
JP2001524116A (ja) 1997-04-18 2001-11-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
HUP0100926A3 (en) 1998-02-26 2003-03-28 Neurogen Corp Branford Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists
MXPA00009569A (es) 1998-03-31 2002-08-06 Acadia Pharm Inc Compuestos con actividad en receptores muscarinicos.
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
BR9913222A (pt) 1998-08-26 2001-10-16 Aventis Pharma Ltd Aza-biciclos que modulam a inibição de adesão das células
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE60039359D1 (de) 1999-09-04 2008-08-14 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
AU2002303264A1 (en) 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2003090748A1 (fr) 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
EP1602645A4 (en) 2003-03-07 2008-12-03 Astellas Pharma Inc NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
MXPA06001636A (es) 2003-08-13 2006-04-28 Amgen Inc Antagonista del receptor de la hormona concentradora de melanina.
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
NZ588799A (en) * 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
JP5007235B2 (ja) 2004-12-20 2012-08-22 ジェネンテック， インコーポレイテッド Ｉａｐのピロリジンインヒビター
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
JP4955009B2 (ja) 2005-11-11 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー 凝固因子Ｘａの阻害剤としての炭素環式縮合環アミン
RU2451025C2 (ru) * 2005-12-19 2012-05-20 Дженентек, Инк. Ингибиторы iap
US7674802B2 (en) 2005-12-21 2010-03-09 Decode Genetics, Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
AU2007307763A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
MX2009005938A (es) 2006-12-07 2009-06-17 Novartis Ag 6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas.
WO2008109180A2 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
JP5298128B2 (ja) 2007-08-08 2013-09-25 グラクソスミスクライン エルエルシー 癌の治療用のＩＧＦ−１Ｒ阻害剤としての２−［（２−｛フェニルアミノ｝−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）アミノ］ベンズアミド誘導体
WO2009067233A1 (en) 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
EP2242362A4 (en) 2008-01-24 2012-04-11 Tetralogic Pharm Corp INHIBITORS OF APOPTOSIS PROTEINS
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
CN102427731B (zh) 2009-02-27 2015-05-13 英安塔制药有限公司 丙型肝炎病毒抑制剂
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
SG175877A1 (en) 2009-05-04 2011-12-29 Plexxikon Inc Compounds and methods for inhibition of renin, and indications therefor
US8415486B2 (en) 2009-05-28 2013-04-09 Tetralogic Pharmaceuticals Corp. IAP inhibitors
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
AU2012319188B2 (en) 2011-10-03 2016-11-24 Sloan-Kettering Institute For Cancer Research Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
AU2013202982C1 (en) 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
PL3083616T3 (pl) 2013-12-20 2021-12-06 Astex Therapeutics Limited Bicykliczne związki heterocykliczne i ich zastosowania w terapii
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
CN120247907A (zh) 2020-05-04 2025-07-04 大塚制药株式会社 Iap拮抗剂化合物和中间体及其合成方法
PL4146617T3 (pl) 2020-05-04 2025-12-08 Taiho Pharmaceutical Co., Ltd. Sposoby syntezy bezwodnego kwasu mlekowego
JP2025508016A (ja) 2022-03-04 2025-03-21 大鵬薬品工業株式会社 Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法
CA3266274A1 (en) 2022-08-31 2024-03-07 Taiho Pharmaceutical Co., Ltd. Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143726A1 (en) 2011-04-21 2012-10-26 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Also Published As

Publication number Publication date
SA516371360B1 (ar) 2019-02-10
CA2933939A1 (en) 2015-06-25
MX380469B (es) 2025-03-12
ES2883289T3 (es) 2021-12-07
AU2014369446B2 (en) 2018-11-22
JP6735369B2 (ja) 2020-08-05
AU2019200840C1 (en) 2021-03-25
JP2020183409A (ja) 2020-11-12
PH12016501139B1 (en) 2016-07-18
US20180065959A1 (en) 2018-03-08
JP6470756B2 (ja) 2019-02-13
US11225476B2 (en) 2022-01-18
PL3083616T3 (pl) 2021-12-06
US11643410B2 (en) 2023-05-09
CN109336883B (zh) 2022-06-14
LT3083616T (lt) 2021-09-10
EP3686200A2 (en) 2020-07-29
EP3083616A1 (en) 2016-10-26
CN105829310A (zh) 2016-08-03
AU2014369446C1 (en) 2020-03-12
EP3083616B1 (en) 2021-06-09
SG10201808102WA (en) 2018-10-30
NZ719905A (en) 2019-10-25
JP2019070030A (ja) 2019-05-09
JP7110279B2 (ja) 2022-08-01
IL246239A0 (en) 2016-08-02
KR20160095160A (ko) 2016-08-10
CN109336883A (zh) 2019-02-15
BR122022015241B1 (pt) 2023-09-26
RU2696310C1 (ru) 2019-08-01
TW201609724A (zh) 2016-03-16
SI3083616T1 (sl) 2021-12-31
DK3083616T3 (da) 2021-08-30
TWI649319B (zh) 2019-02-01
CY1124436T1 (el) 2022-07-22
RU2016129472A (ru) 2018-01-25
HUE056297T2 (hu) 2022-02-28
AU2014369446A1 (en) 2016-06-02
CN105829310B (zh) 2019-04-12
US20220204503A1 (en) 2022-06-30
PH12016501139A1 (en) 2016-07-18
EP3686200A3 (en) 2020-09-09
JP2017500338A (ja) 2017-01-05
US9783538B2 (en) 2017-10-10
US12202828B2 (en) 2025-01-21
US10618895B2 (en) 2020-04-14
BR112016014561A2 (enExample) 2017-08-08
US20200325134A1 (en) 2020-10-15
IL246239B (en) 2019-08-29
SG11201604795RA (en) 2016-07-28
CA2933939C (en) 2021-03-16
MX2016008131A (es) 2016-09-16
MY193649A (en) 2022-10-21
CN115368356A (zh) 2022-11-22
AU2019200840B2 (en) 2020-05-28
WO2015092420A1 (en) 2015-06-25
US20170029419A1 (en) 2017-02-02
HRP20211406T1 (hr) 2021-12-10
US20250296930A1 (en) 2025-09-25
AU2019200840A1 (en) 2019-02-28
CN115368356B (zh) 2025-05-09
MY186311A (en) 2021-07-08
RS62301B1 (sr) 2021-09-30
SMT202100497T1 (it) 2021-09-14
NZ758528A (en) 2022-05-27
PT3083616T (pt) 2021-08-12
US20230227450A1 (en) 2023-07-20
BR112016014561B1 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
US12202828B2 (en) Bicyclic heterocycle compounds and their uses in therapy
KR102299834B1 (ko) 바이사이클릭 헤테로사이클 화합물 및 치료에서의 그것의 용도
NZ758528A9 (en) Bicyclic heterocycle compounds and their uses in therapy
US20150291586A1 (en) Bicyclic heterocycle compounds and their uses in therapy
HK40084234A (en) Bicyclic heterocycle compounds and their uses in therapy
HK40033709A (en) Bicyclic heterocycle compounds and their uses in therapy
HK40084234B (zh) 双环杂环化合物及其治疗用途
HK1262092A1 (en) Bicyclic heterocycle compounds and their uses in therapy
HK1262092B (en) Bicyclic heterocycle compounds and their uses in therapy
HK1230598B (en) Bicyclic heterocycle compounds and their uses in therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160715

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210603

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220608

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220608

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250526

Start annual number: 4

End annual number: 4